The US Food and Drug Administration (FDA) has proposed a regulatory framework that could allow multiple patient-specific genome-editing therapies for rare genetic diseases to be covered under a single approval, potentially reducing the need for separate clinical trials as additional treatment variants are developed, according to a press release from the US Department of Health and Human Services (HHS).
The October 27 draft guidance, Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management, addresses how developers can seek approval for therapies designed to target genetic mutations that differ among patients, including those with ultra-rare conditions for which no treatment currently exists. . Because these mutations can vary among patients with the same disease, a single treatment may not be suitable for everyone. The guidance outlines how developers could obtain approval for products tailored to individual genetic variants.
Under the proposed framework, a single biologics license application (BLA) could encompass multiple individualized versions of a genome-editing product. An individualized feature space (IFS) would establish predefined boundaries for how a product may vary among patients while remaining within the scope of a single BLA. Following initial approval, developers could add new patient-specific variants that fall within those boundaries without conducting additional clinical trials, provided laboratory testing demonstrates adequate safety and activity. The streamlined process would rely on clinical trials supporting the original BLA and laboratory (in vitro) data for each new variant.
"This guidance gives sponsors the regulatory clarity they need to develop therapies tailored to each patient’s unique genetic makeup," said Kyle Diamantas, JD, acting FDA commissioner, in the HHS press release.
The guidance also addresses manufacturing, safety testing, unintended genetic changes, and product naming and labeling. These considerations are intended to support the assessment of individualized products while maintaining safety and effectiveness standards.
Karim Mikhail, BPharm, MS, director of the FDA's Center for Biologics Evaluation and Research, described the guidance as "a critical step forward in FDA’s efforts to support the development of individualized therapies for patients with rare genetic diseases."
The announcement does not constitute approval of any new genome-editing therapy. The draft guidance provides nonbinding recommendations, and no product-specific clinical trial results or safety findings accompanied its release.
Separately, the Centers for Medicare & Medicaid Services (CMS) announced plans to expand its voluntary Cell and Gene Therapy Access Model beyond sickle cell disease to include treatments for other conditions, with the goal of improving access to these therapies among Medicaid beneficiaries.
"A medical breakthrough only matters to patients if they can get it," said CMS Administrator Mehmet Oz, MD, in the HHS press release. "CMS is bringing state Medicaid programs together to negotiate with drug manufacturers to help put life-changing therapies within reach."
Under the existing model, CMS negotiates outcomes-based agreements with manufacturers on behalf of state Medicaid programs. According to CMS, an initial evaluation found that centralized negotiations reduced states' administrative burdens and strengthened negotiating leverage by pooling beneficiaries.
CMS plans to invite additional manufacturers and enable negotiations to begin sooner after FDA approval or licensure, including for previously approved or licensed therapies. A forthcoming Request for Applications will outline participation in the expanded model.
The FDA is accepting comments on the draft guidance within 30 days of its publication in the Federal Register, under docket FDA-2026-D-11783. CMS has not announced a release date for the expanded model's manufacturer application process.
Sources: HHS